We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Hold Charles River Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
Charles River stock has surged 109.8% in a year, outperforming the industry's 11.8% gain.
CRL's DSA bookings jumped 32% to $652 million in Q3 2026, while backlog climbed to $2.03 billion.
CRL expects 2026 reported revenues to decline 1.5-2%, despite organic growth of at least 1.5%.
Charles River Laboratories International, Inc.’s (CRL - Free Report) Discovery and Safety Assessment (“DSA”) segment is showing improving demand, bookings and backlog, supporting its growth prospects. Also, a strong solvency position bodes well for the stock. Yet, fierce competitive pressure and unfavorable foreign exchange remain key risks.
Over the past year, this Zacks Rank #3 (Hold) company’s shares have surged 109.8% compared with the industry’s 11.8% growth. The S&P 500 composite has risen 10.6% over the same period.
The renowned, non-clinical global drug development company has a market capitalization of $16.08 billion. Charles River has an earnings yield of 3.4%. The company surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 5.6%.
Let’s delve deeper.
Upsides for CRL Stock
DSA, a Potential Growth Driver: Charles River remains a leading provider of outsourced discovery, non-clinical development and regulated safety testing services. In the third quarter of 2026, DSA organic revenues increased 5.9%, accelerating from 0.2% growth in the second quarter. Net bookings rose 32% year over year to $652 million, while backlog increased to $2.03 billion from $1.97 billion in the preceding quarter.
Net book-to-bill reached 1.09x, marking the fourth consecutive quarter above 1x and averaging approximately 1.1x over that period. Higher regulated safety assessment volumes, including nonhuman primate (NHP) studies and bioanalysis, supported the recovery. The Cambodia NHP sourcing assets are already helping reduce costs, contributing to a 140-basis-point expansion in third-quarter non-GAAP DSA margin to 26.8%.
Solvency Position: Charles River ended the third quarter of 2026 with $200.4 million in cash and cash equivalents, compared with $192 million at the end of the second quarter. Long-term debt, net and finance leases totaled $2.44 billion, down from $2.62 billion in the second quarter. Management reported sequentially improved net leverage of 2.3x. Operating cash flow reached $474.9 million during the first nine months of 2026 compared with $590.1 million a year earlier. Third-quarter free cash flow increased $29 million year over year to $207 million. The company repurchased approximately $324 million of shares during the first nine months while funding strategic acquisitions and organic investments.
Image Source: Zacks Investment Research
Concerns for CRL
Competitive Intensity Across Segments: Charles River competes on scientific expertise, quality, responsiveness, innovation, capacity and price across RMS, DSA and Manufacturing. Its investments in digital pathology, AI-enabled workflows, laboratory sciences and client connectivity aim to improve differentiation. However, customers continue to compare providers on pricing and technical capabilities. If demand recovery remains gradual, the cost of maintaining technology, scientific talent and client support could limit operating leverage even as Charles River refines its portfolio.
Foreign Exchange Can Obscure Underlying Trends: Charles River's revised 2026 outlook projects a 1.5% to 2.0% decline in reported revenues, despite expectations for organic revenue growth of at least 1.5%. The outlook includes an approximately 4.5% impact from divestitures and a favorable foreign-exchange contribution of 0.5% to 1.0%. Third-quarter reported revenues declined 2.2% year over year to $982.7 million, even as organic revenues increased 4.7%. This divergence illustrates how portfolio changes and currency movements can obscure underlying demand trends. Given Charles River's international operations, currency fluctuations remain a source of uncertainty for reported growth and period-to-period comparisons.
CRL Stock Estimate Trend
The Zacks Consensus Estimate for CRL’s 2026 earnings has increased 0.4% to $11.41 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $3.94 billion, suggesting a 1.8% decrease from the year-ago reported number.
Glaukos has an earnings yield of 0.2% against the industry’s negative 1.3% yield. Shares of the company have gained 175.3% compared with the industry’s 5.2% growth over the past year. GKOS’ earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 138.6%.
IDEXX Laboratories, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX’s shares have plunged 4.8% against the industry’s 3% growth over the past year.
Intuitive Surgical, presently carrying a Zacks Rank #2, has an earnings yield of 2.6% against the industry’s negative 1.3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 15.1%. ISRG’s shares have lost 21.4% against the industry’s 5.2% growth over the past year.
Image: Bigstock
Should You Continue to Hold Charles River Stock in Your Portfolio?
Key Takeaways
Charles River Laboratories International, Inc.’s (CRL - Free Report) Discovery and Safety Assessment (“DSA”) segment is showing improving demand, bookings and backlog, supporting its growth prospects. Also, a strong solvency position bodes well for the stock. Yet, fierce competitive pressure and unfavorable foreign exchange remain key risks.
Over the past year, this Zacks Rank #3 (Hold) company’s shares have surged 109.8% compared with the industry’s 11.8% growth. The S&P 500 composite has risen 10.6% over the same period.
The renowned, non-clinical global drug development company has a market capitalization of $16.08 billion. Charles River has an earnings yield of 3.4%. The company surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 5.6%.
Let’s delve deeper.
Upsides for CRL Stock
DSA, a Potential Growth Driver: Charles River remains a leading provider of outsourced discovery, non-clinical development and regulated safety testing services. In the third quarter of 2026, DSA organic revenues increased 5.9%, accelerating from 0.2% growth in the second quarter. Net bookings rose 32% year over year to $652 million, while backlog increased to $2.03 billion from $1.97 billion in the preceding quarter.
Net book-to-bill reached 1.09x, marking the fourth consecutive quarter above 1x and averaging approximately 1.1x over that period. Higher regulated safety assessment volumes, including nonhuman primate (NHP) studies and bioanalysis, supported the recovery. The Cambodia NHP sourcing assets are already helping reduce costs, contributing to a 140-basis-point expansion in third-quarter non-GAAP DSA margin to 26.8%.
Solvency Position: Charles River ended the third quarter of 2026 with $200.4 million in cash and cash equivalents, compared with $192 million at the end of the second quarter. Long-term debt, net and finance leases totaled $2.44 billion, down from $2.62 billion in the second quarter. Management reported sequentially improved net leverage of 2.3x. Operating cash flow reached $474.9 million during the first nine months of 2026 compared with $590.1 million a year earlier. Third-quarter free cash flow increased $29 million year over year to $207 million. The company repurchased approximately $324 million of shares during the first nine months while funding strategic acquisitions and organic investments.
Image Source: Zacks Investment Research
Concerns for CRL
Competitive Intensity Across Segments: Charles River competes on scientific expertise, quality, responsiveness, innovation, capacity and price across RMS, DSA and Manufacturing. Its investments in digital pathology, AI-enabled workflows, laboratory sciences and client connectivity aim to improve differentiation. However, customers continue to compare providers on pricing and technical capabilities. If demand recovery remains gradual, the cost of maintaining technology, scientific talent and client support could limit operating leverage even as Charles River refines its portfolio.
Foreign Exchange Can Obscure Underlying Trends: Charles River's revised 2026 outlook projects a 1.5% to 2.0% decline in reported revenues, despite expectations for organic revenue growth of at least 1.5%. The outlook includes an approximately 4.5% impact from divestitures and a favorable foreign-exchange contribution of 0.5% to 1.0%. Third-quarter reported revenues declined 2.2% year over year to $982.7 million, even as organic revenues increased 4.7%. This divergence illustrates how portfolio changes and currency movements can obscure underlying demand trends. Given Charles River's international operations, currency fluctuations remain a source of uncertainty for reported growth and period-to-period comparisons.
CRL Stock Estimate Trend
The Zacks Consensus Estimate for CRL’s 2026 earnings has increased 0.4% to $11.41 in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $3.94 billion, suggesting a 1.8% decrease from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Glaukos (GKOS - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Glaukos has an earnings yield of 0.2% against the industry’s negative 1.3% yield. Shares of the company have gained 175.3% compared with the industry’s 5.2% growth over the past year. GKOS’ earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 138.6%.
GKOS carries a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX Laboratories, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX’s shares have plunged 4.8% against the industry’s 3% growth over the past year.
Intuitive Surgical, presently carrying a Zacks Rank #2, has an earnings yield of 2.6% against the industry’s negative 1.3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 15.1%. ISRG’s shares have lost 21.4% against the industry’s 5.2% growth over the past year.